Chugai Seiyaku Kabushiki Kaisha

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Yoshimi Imaeda

Daisuke Kameoka

Oliver Boris Stauch

Toshiyuki Morichika

Terutoshi Maeda

Jun Kikuchi

Masaya Kakuta

Hidefumi Mizushima

The problem to be solved is to provide a humanized anti-IL-6 receptor antibody AMA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.

High concentration antibody-containing liquid formulation

The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.

The problem to be solved is to provide an antibody-containing formulation which is stable and suited for subcutaneous administration, wherein dimerization and deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and methionine.

Antibody-containing solution formulations including a sugar as a stabilizer. Said solution formulations can further include a surfactant as a stabilizer.

Growing community of inventors

Tokyo, Japan

Yoshimi Imaeda